文献速递头颈外科

临床淋巴结阴性口腔鳞状细胞癌患者颈部IV区跳跃转移率的系统评价与Meta分析

Assessment of the Rate of Skip Metastasis to Neck Level IV in Patients With Clinically Node-Negative Neck Oral Cavity Squamous Cell Carcinoma: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2019-01-01

该Meta分析纳入11项回顾性研究和2项前瞻性随机临床试验(共1359例cN0口腔鳞状细胞癌患者),评估颈部IV区跳跃转移率。固定效应模型显示IV区受累率为2.53%(95%CI 1.64%-3.55%),跳跃转移率为0.50%(95%CI 0.09%-1.11%)。作者结论认为跳跃转移率很低,肩胛舌骨上颈清扫对该组患者已足够。

要点

  • cN0口腔鳞状细胞癌患者颈部IV区跳跃转移率固定效应模型为0.50%(95%CI 0.09%-1.11%)。
  • 颈部IV区受累率固定效应模型为2.53%(95%CI 1.64%-3.55%)。
  • 作者结论认为肩胛舌骨上颈清扫对cN0口腔鳞状细胞癌患者已足够。

核心结论

  • 该Meta分析显示cN0口腔鳞状细胞癌患者颈部IV区跳跃转移率很低,作者结论认为肩胛舌骨上颈清扫对该组患者已足够。

研究设计与样本

  • 系统评价与Meta分析,检索Embase、PubMed和Google Scholar数据库1970年1月1日至2017年12月31日发表的文章。
  • 纳入11项回顾性研究和2项前瞻性随机临床试验,共1359例患者。
  • 采用固定效应模型合并数据并估计95%CI,遵循Meta-analysis of Observational Studies in Epidemiology指南。

主要发现

  • cN0患者颈部IV区受累率范围为0%至11.40%,固定效应模型为2.53%(95%CI 1.64%-3.55%)。
  • 跳跃转移率范围为0%至5.50%,固定效应模型为0.50%(95%CI 0.09%-1.11%)。
  • 涉及颈部I至III区时,IV区跳跃转移率未显著增加。
  • 肿瘤分期和原发部位肿瘤未显著影响跳跃转移率。

临床怎么用

  • 作者结论认为,对于cN0口腔鳞状细胞癌患者,肩胛舌骨上颈清扫已足够。
  • 作者指出,颈清扫中遇到 allegedly 阳性淋巴结并不预示IV区受累率高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The rate of skip metastasis to neck level IV in patients with clinically node-negative neck (cN0) oral cavity squamous cell carcinoma (OCSCC) remains controversial. OBJECTIVE: To provide a high level of evidence using a meta-analysis on the rate of skip metastasis to level IV in this subset of patients. DATA SOURCES: The Embase, PubMed, and Google Scholar databases were searched for articles published during the period of January 1, 1970, through December 31, 2017, using the following key terms: neck dissection, N0 neck, squamous cell carcinoma, skip metastasis, radical neck dissection, lymph node management, neck metastasis, oral cavity cancer, and tongue cancer. Some terms were also used in combination, and the reference section of each article was searched for additional potentially relevant publications. Data were analyzed from January 8 through 11, 2018. STUDY SELECTION: Inclusion criteria were all cohorts, including from any randomized clinical trial, case-control study, case study, and case report; studies of patients with the histopathologic diagnosis of OCSCC; and studies that differentiated data between skip metastasis and sequential metastasis to neck level IV. Of the 115 articles retrieved from the literature, 11 retrospective studies and 2 prospective randomized clinical trials (n = 1359 patients) were included. DATA EXTRACTION AND SYNTHESIS: Meta-analysis of Observational Studies in Epidemiology guidelines were followed. Fixed-effects model and 95% CIs were estimated, and data of included studies were pooled using a fixed-effects model. MAIN OUTCOMES AND MEASURES: Overall proportion of neck involvement and the rate of level IV skip metastasis. Subgroup analysis for primary site and tumor staging. RESULTS: The rate of level IV involvement in patients with cN0 ranged between 0% and 11.40% with a fixed-effects model of 2.53% (95% CI, 1.64%-3.55%). The rate of skip metastasis ranged from 0% to 5.50% with a fixed-effects model of 0.50% (95% CI, 0.09%-1.11%). The rate of level IV skip metastasis did not increase significantly in cases that involved neck levels I through III. Tumor staging and primary site tumor did not significantly affect the rate of skip metastasis. CONCLUSIONS AND RELEVANCE: This meta-analysis showed very low rates of skip metastasis to neck level IV in patients diagnosed with cN0 OCSCC. Encountering an allegedly positive lymph node during neck dissection does not portend high rates of level IV involvement. Supraomohyoid neck dissection is therefore adequate for this subset of patients.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Warshavsky A, Rosen R, Nard-Carmel N, et al. Assessment of the Rate of Skip Metastasis to Neck Level IV in Patients With Clinically Node-Negative Neck Oral Cavity Squamous Cell Carcinoma: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2019. PMID: 31070693. doi:10.1001/jamaoto.2019.0784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。